Tussilagone suppresses triple-negative breast cancer progression by inhibiting the TLR4/NF-κB pathway and enhancing anti-tumor immunity

This study demonstrated that TUS inhibited TNBC progression by suppressing the TLR4/NF-κB pathway, reversing EMT, and modulating TIME. These findings support the potential of TUS as a promising therapeutic candidate for TNBC and underscore the need for further clinical investigation.